TNYA Stock Analysis: Buy, Sell, or Hold?
TNYA - Tenaya Therapeutics, Inc. Common Stock
$0.70
0.01 (0.98%)
▲
5d:
-4.23%
30d:
-9.8%
90d:
-11.73%
BUY
HIGH Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When TNYA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: TNYA shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: TNYA shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: TNYA is currently trading at $0.70, which is considered oversold relative to its 30-day fair value range of $0.71 to $0.81. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.8) compared to its historical average (10.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TNYA is in a strong uptrend. The price is currently testing key support at $0.68. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TNYA scores 72/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $3.20 (+358.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TNYA is in a strong uptrend. The price is currently testing key support at $0.68. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TNYA scores 72/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $3.20 (+358.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.71 -
$0.81
Company Quality Score
69/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
95.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (72/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 358.9% below Wall St target ($3.20)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- BULLISH: Bottoming setup score 72/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$0.71 -
$0.81
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.68
Resistance Level
$0.79
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.78
Wall Street Target
$3.20
(+358.9%)
PE vs Historical
-1.8 vs 10.3
CHEAP
Share & Embed Analysis
Last updated: August 22, 2026 8:32 PM ET
Data refreshes hourly during market hours. Next update: 9:32 PM
Data refreshes hourly during market hours. Next update: 9:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TNYA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Group Gp Lp Column III
SELL
3511826 shares
2026-02-25
Group Gp Lp Column III
SELL
658440 shares
2026-02-24
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$131 | 38 SELL |
